Postoperative adverse cardiac events in acute myocardial infarction with high thrombus load and best time for stent implantation

Table 1 Comparison of thrombolysis in myocardial infarction flow grades and thrombolysis in myocardial infarction myocardial perfusion grade grading after stent implantation between the two groups, n (%)

Group	Deferred group (n = 92)	Immediate group (n = 72)	Z	P value
TIMI flow grades			-2.302	0.021
0 degree	0 (0)	0 (0)
1 degree	2 (2.17)	6 (8.33)
2 degree	24 (26.09)	26 (36.11)
3 degree	66 (71.74)	40 (55.56)
TMPG grading			-1.836	0.066
0 degree	0 (0.00)	0 (0.00)
1 degree	3 (3.26)	8 (11.11)
2 degree	28 (30.43)	25 (34.72)
3 degree	61 (66.30)	39 (54.17)

TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade.

Table 2 Comparison of ST segment fall rate at 90 min after percutaneous coronary intervention, n (%)

Group	n	≥ 50%	< 50%
Delayed Group	92	76 (82.61)	16 (17.39)
Immediate group	72	56 (77.78)	16 (22.22)
χ2		0.600
P value		0.438

Table 3 Single factor analysis of major adverse cardiovascular events occurrence

Data	MACE group (n = 29)	Non-MACE group (n = 135)	t/χ2	P value
Age (yr)	63.9 ± 7.7	65.0 ± 8.1	-0.669	0.504
BMI (kg/m2)	24.1 ± 2.0	23.8 ± 2.4	0.628	0.531
HR (times/min)	91.6 ± 8.2	93.0 ± 7.6	-0.888	0.376
Number of implanted stents	1.85 ± 0.45	1.98 ± 0.50	-1.292	0.198
Gender			1.002	0.317
Male	18 (62.07)	70 (51.85)
Female	11 (37.93)	65 (48.15)
Diabetes			4.314	0.038
Yes	9 (31.03)	20 (14.81)
No	20 (68.97)	115 (85.19)
Hypertension			3.758	0.053
Yes	13 (44.83)	36 (26.67)
No	16 (55.17)	99 (73.33)
Hyperlipidemia			1.851	0.174
Yes	18 (62.07)	65 (48.15)
No	11 (37.93)	70 (51.85)
Smoking			1.851	0.174
Yes	11 (37.93)	34 (25.19)
No	18 (62.07)	101 (74.81)
Infarct related blood vessel			5.729	0.126
Anterior descending branch	16 (55.17)	43 (31.85)
Circumflex	4 (13.79)	29 (21.48)
Left main stem	2 (6.9)	11 (8.15)
Right coronary artery	7 (24.14)	52 (38.52)
Killp rating			0.805	0.370
1-2 degree	22 (75.86)	112 (82.96)
3-4 degree	7 (24.14)	23 (17.04)
Use ACEI			1.277	0.258
Yes	18 (62.07)	98 (72.59)
No	11 (37.93)	37 (27.41)
Use beta blockers			0.818	0.366
Yes	21 (72.41)	108 (80.00)
No	8 (27.59)	27 (20.00)
TIMI grading			6.046	0.014
3 degree	13 (44.83)	93 (68.89)
< 3 degree	16 (55.17)	42 (31.11)
TMPG grading			3.861	0.049
3 degree	13 (44.83)	87 (64.44)
< 3 degree	16 (55.17)	48 (35.56)
Timing of stent implantation			6.683	0.010
Immediately	19 (65.52)	53 (39.26)
Extension	10 (34.48)	82 (60.74)
Intraoperative use of tirofiban			4.599	0.032
Yes	17 (58.62)	105 (77.78)
No	12 (41.38)	30 (22.22)
CK-MB peak (U/L)	226.4 ± 44.1	218.0 ± 40.8	0.992	0.323
WBC (109/L)	12.63 ± 2.01	11.18 ± 1.80	3.854	0.000
N (109/L)	9.80 ± 1.14	15.13 ± 0.63	-35.022	0.000
RDW	13.54 ± 2.08	12.61 ± 1.86	2.392	0.018
UA (μmol/L)	368.1 ± 42.2	340.7 ± 38.5	3.418	0.001
hs-CRP (mg/L)	10.58 ± 2.81	8.62 ± 2.51	3.734	0.000

MACE: Major adverse cardiovascular events; BMI: Body mass index; HR: Heart rate; ACEI: Angiotensin-converting enzyme inhibitor; TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade; WBC: White blood cells; N: Neutrophils; RDW: Red blood cell distribution width; UA: Uric acid; hs-CRP: High-sensitivity C-reactive protein.

Table 4 Logistic regression analysis of factors affecting major adverse cardiovascular events occurrence

Factor	b	SE	Walds	P value	OR	95%CI
Diabetes	0.471	0.288	2.675	0.166	1.602	0.911	2.816
TIMI rating	-0.552	0.24	5.290	0.033	0.576	0.360	0.922
TMPG rating	-0.464	0.317	2.142	0.247	0.629	0.338	1.170
Timing of stent implantation	0.758	0.336	5.089	0.036	2.134	1.105	4.123
Intraoperative use of tirofiban	-0.392	0.15	6.830	0.011	0.676	0.504	0.907
WBC	0.608	0.275	4.888	0.042	1.837	1.071	3.149
N	0.418	0.336	1.548	0.304	1.519	0.786	2.935
RDW	0.577	0.22	6.879	0.009	1.781	1.157	2.741
UA	0.718	0.484	2.201	0.243	2.050	0.794	5.294
hs-CRP	0.466	0.215	4.698	0.045	1.594	1.046	2.429

MACE: Major adverse cardiovascular events; TIMI: Thrombolysis in myocardial infarction; TMPG: TIMI myocardial perfusion grade; WBC: White blood cells; N: Neutrophils; RDW: Red blood cell distribution width; UA: Uric acid; hs-CRP: High-sensitivity C-reactive protein.